Kurt von Emster
Director/Board Member chez JASPER THERAPEUTICS, INC.
Fortune : 62 184 $ au 31/03/2024
Profil
Konrad Hans von Emster is the founder of the Franklin Biotechnology Discovery Fund, founded in 2001, where he held the title of Portfolio Manager.
He was also the founder of venBio Partners LLC, founded in 2009, where he held the title of Managing Partner.
Currently, Mr. von Emster holds the position of Director at SFJ Pharmaceuticals, Inc., Orbus Therapeutics, Inc., Tizona Therapeutics, Inc., Abingworth Bioventures GP Ltd., Jasper Tx Corp., Trishula Therapeutics, Inc., and Jasper Therapeutics, Inc. He is an Independent Director at Jasper Therapeutics, Inc. In the past, Mr. von Emster has held positions such as Chairman at Kesios Therapeutics Ltd.
and Vera Therapeutics, Inc. He was also a Managing Director at MPM BioEquities Adviser LLC from 2000 to 2009.
Additionally, he served as an Independent Director at Somaxon Pharmaceuticals, Inc. from 2005 to 2013 and as a Director at Cytos Biotechnology AG from 2012 to 2015.
Mr. von Emster's education includes an undergraduate degree from the University of California, Santa Barbara, which he received in 1989.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/10/2023 | 2 118 ( 0,01% ) | 62 184 $ | 31/03/2024 |
Postes actifs de Kurt von Emster
| Sociétés | Poste | Début |
|---|---|---|
| JASPER THERAPEUTICS, INC. | Director/Board Member | 24/09/2021 |
Jasper Tx Corp.
 Jasper Tx Corp. BiotechnologyHealth Technology Jasper Tx Corp. operates as a biotechnology company. It engages in the clinical development of novel therapies. The company was founded by Susan S. Prohaska and Judith Shizuru and is headquartered in Mountain View, CA. | Director/Board Member | 01/11/2019 |
SFJ Pharmaceuticals, Inc.
 SFJ Pharmaceuticals, Inc. BiotechnologyHealth Technology SFJ Pharmaceuticals, Inc. develops pharmaceuticals drugs. It offers drugs for cancer, kidney, thyroid, leukemia, and lung cancer. The company was founded by Roberto DeBenedetto in January 2009 and is headquartered in Pleasanton, CA. | Director/Board Member | 01/04/2020 |
Orbus Therapeutics, Inc.
 Orbus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orbus Therapeutics, Inc. operates as a biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases. Its product eflornithine is a novel cytostatic agent, which the firm is developing to treat patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. The company was founded by Robert M. Myers and Jason D. Levin in 1998 and is headquartered in Palo Alto, CA. | Director/Board Member | 01/07/2020 |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Director/Board Member | 01/12/2020 |
Trishula Therapeutics, Inc.
 Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | Director/Board Member | 01/10/2020 |
Abingworth Bioventures GP Ltd.
 Abingworth Bioventures GP Ltd. Other TransportationTransportation Abingworth Bioventures GP Ltd. provides marine cargo handling facilities. The company was founded on March 29, 2012 and is headquartered in London, the United Kingdom. | Director/Board Member | 16/09/2019 |
Broadhaven Capital Partners (Private equity)
 Broadhaven Capital Partners (Private equity) Investment ManagersFinance Broadhaven Capital Partners (Broadhaven Capital Partners) is a private equity subsidiary of Broadhaven Capital Partners LLC founded in 2009 by Gregory Allen Phillips and Gerard von Dohlen. The firm is headquartered in New York. | Private Equity Investor | 01/05/2017 |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. | Private Equity Investor | 01/01/2015 |
| ░░░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Kurt von Emster
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Kurt von Emster
| University of California, Santa Barbara | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| FRANKLIN RESOURCES, INC. | Finance |
| AURINIA PHARMACEUTICALS INC. | Health Technology |
| CRISPR THERAPEUTICS AG | Health Technology |
| VAXCYTE, INC. | Health Technology |
| VERA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 28 |
|---|---|
MPM BioEquities Adviser LLC
 MPM BioEquities Adviser LLC Investment ManagersFinance Founded in 1997 by Ansbert Gadicke and Luke Evnin, MPM BioEquities Adviser LLC is a hedge fund manager located in South San Francisco, California with an additional office in Boston. The firm is a subsidiary of MPM Capital LP, a private equity firm. | Finance |
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
Somaxon Pharmaceuticals, Inc.
 Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | Health Technology |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
Abingworth Management Ltd.
 Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom. | Finance |
| Franklin Biotechnology Discovery Fund | Miscellaneous |
Franklin Advisers, Inc.
 Franklin Advisers, Inc. Investment ManagersFinance Franklin Advisers, Inc. is a mutual fund manager and registered investment advisor headquartered in San Mateo, California. The firm was founded in 1985 and is a subsidiary of Franklin Resources, Inc. (NYSE: BEN), a holding company that, together with its various subsidiaries is referred to as Franklin Templeton Investments. Franklin Advisers provides investment advisory and portfolio management services to US and non-US, registered open-end and closed-end funds and unregistered funds, as well as separate accounts. | Finance |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth LLP is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. | Finance |
Cytos Biotechnology AG
 Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Commercial Services |
Facet, Inc.
 Facet, Inc. Information Technology ServicesTechnology Services Facet, Inc. manufactures software for creating and maintaining libraries. The private company is based in Milwaukee, WI and has no subsidiaries. | Technology Services |
CFA Institute
 CFA Institute Miscellaneous Commercial ServicesCommercial Services CFA Institute operates as non-profit organization, which engages in the provision of chartered financial analyst programs. It offers certificate in investment performance measurement program, investment foundations, and scholarship. The company was founded in 1965 and is headquartered in Charlottesville, VA. | Commercial Services |
CFA Society of San Francisco
 CFA Society of San Francisco Miscellaneous Commercial ServicesCommercial Services CFA Society of San Francisco provides educational services. It offers a multi-review course which provides structured, classroom-based approach to preparing for the examination. The firm focuses on the assigned materials in the study guides from CFA Institute, with an emphasis on the Learning Outcome Statements (LOS). The company was founded in 1929 and is headquartered in San Francisco, CA. | Commercial Services |
| Franklin Templeton Cos. LLC | |
venBio Partners LLC
 venBio Partners LLC Investment ManagersFinance venBio Partners LLC (venBio) is a private equity subsidiary of Venbio Partners LP founded in 2009 by Adelman robert and Goodman corey. The firm is headquartered in San Francisco, California. | Finance |
SFJ Pharmaceuticals, Inc.
SFJ Pharmaceuticals, Inc. BiotechnologyHealth Technology SFJ Pharmaceuticals, Inc. develops pharmaceuticals drugs. It offers drugs for cancer, kidney, thyroid, leukemia, and lung cancer. The company was founded by Roberto DeBenedetto in January 2009 and is headquartered in Pleasanton, CA. | Health Technology |
Broadhaven Capital Partners (Private equity)
Broadhaven Capital Partners (Private equity) Investment ManagersFinance Broadhaven Capital Partners (Broadhaven Capital Partners) is a private equity subsidiary of Broadhaven Capital Partners LLC founded in 2009 by Gregory Allen Phillips and Gerard von Dohlen. The firm is headquartered in New York. | Finance |
Orbus Therapeutics, Inc.
Orbus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orbus Therapeutics, Inc. operates as a biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases. Its product eflornithine is a novel cytostatic agent, which the firm is developing to treat patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. The company was founded by Robert M. Myers and Jason D. Levin in 1998 and is headquartered in Palo Alto, CA. | Health Technology |
| Franklin Templeton Switzerland Ltd. | |
Kesios Therapeutics Ltd.
 Kesios Therapeutics Ltd. BiotechnologyHealth Technology Kesios Therapeutics Ltd. provides biotechnology services. It develops novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company was founded by Menotti Ruvo, Laura Tornatore, and Guido Franzoso on July 13, 2012 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
Attenua, Inc.
 Attenua, Inc. Pharmaceuticals: MajorHealth Technology Attenua, Inc. engages in the provision of biopharmaceutical services. The company was founded by Jing Liang and is headquartered in San Mateo, CA. | Health Technology |
Abingworth Bioventures GP Ltd.
Abingworth Bioventures GP Ltd. Other TransportationTransportation Abingworth Bioventures GP Ltd. provides marine cargo handling facilities. The company was founded on March 29, 2012 and is headquartered in London, the United Kingdom. | Transportation |
Jasper Tx Corp.
Jasper Tx Corp. BiotechnologyHealth Technology Jasper Tx Corp. operates as a biotechnology company. It engages in the clinical development of novel therapies. The company was founded by Susan S. Prohaska and Judith Shizuru and is headquartered in Mountain View, CA. | Health Technology |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | Health Technology |
| Jasper Therapeutics, Inc. | |
Launch Therapeutics, Inc.
 Launch Therapeutics, Inc. Financial ConglomeratesFinance Launch Therapeutics, Inc. provides investment and therapies development services. The CEO of the American company is Anshul Thakral. | Finance |
